- Previous Close
12.38 - Open
12.32 - Bid 11.73 x 100
- Ask 11.93 x 100
- Day's Range
11.77 - 12.47 - 52 Week Range
5.45 - 15.77 - Volume
168,073 - Avg. Volume
237,450 - Market Cap (intraday)
385.837M - Beta (5Y Monthly) 2.07
- PE Ratio (TTM)
-- - EPS (TTM)
-0.93 - Earnings Date May 6, 2025 - May 12, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.57
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides Physician Tablet, Patient Data Management System, and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
www.neuropace.comRecent News: NPCE
View MorePerformance Overview: NPCE
Trailing total returns as of 3/28/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NPCE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NPCE
View MoreValuation Measures
Market Cap
385.84M
Enterprise Value
406.42M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.32
Price/Book (mrq)
48.15
Enterprise Value/Revenue
5.09
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-33.97%
Return on Assets (ttm)
-13.39%
Return on Equity (ttm)
-189.35%
Revenue (ttm)
79.91M
Net Income Avi to Common (ttm)
-27.14M
Diluted EPS (ttm)
-0.93
Balance Sheet and Cash Flow
Total Cash (mrq)
52.76M
Total Debt/Equity (mrq)
915.24%
Levered Free Cash Flow (ttm)
-10.7M